ViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars.
After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars."
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-first-quarter-2023-financial-results-to-be-held-after-market-on-may-10-2023-301819978.html
SOURCE ViewRay, Inc.